VXRT soared 23% in after-hours sessions as Vaxart Inc (NASDAQ:VXRT) reports data from oral COVID-19 vaccine Phase 1 study suggesting broad cross-reactivity against other coronaviruses.
Vaxart announced today at its key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the company’s first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity.
The Phase I open-label study is intended to evaluate the safety and immunogenicity of Vaxart’s vaccine candidate. Data obtained from Vaxart’s oral COVID-19 vaccine Phase I trial showed substantial CD8+ T-cell responses, as measured by IFN-g and TNF-a induction.
In a comparative experiment conducted by Vaxart, Phase I study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna (MRNA) or Pfizer (PFE) mRNA vaccine, indicating the mRNA vaccines induced fewer T-cell responses.
The Vaxart vaccine candidate elicited a T cell response against SARS-Cov-2, as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43
After falling over 25.50% in regular trading on earnings miss, VXRT stock is up 23% in the extended session.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.